Cargando…
Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS
BACKGROUND: CCR5-restricted (R5) human immunodeficiency virus type 1 (HIV-1) variants cause CD4+ T-cell loss in the majority of individuals who progress to AIDS, but mechanisms underlying the pathogenicity of R5 strains are poorly understood. To better understand envelope glycoprotein (Env) determin...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2225424/ https://www.ncbi.nlm.nih.gov/pubmed/18076768 http://dx.doi.org/10.1186/1742-4690-4-89 |
_version_ | 1782149654581870592 |
---|---|
author | Sterjovski, Jasminka Churchill, Melissa J Ellett, Anne Gray, Lachlan R Roche, Michael J Dunfee, Rebecca L Purcell, Damian FJ Saksena, Nitin Wang, Bin Sonza, Secondo Wesselingh, Steven L Karlsson, Ingrid Fenyo, Eva-Maria Gabuzda, Dana Cunningham, Anthony L Gorry, Paul R |
author_facet | Sterjovski, Jasminka Churchill, Melissa J Ellett, Anne Gray, Lachlan R Roche, Michael J Dunfee, Rebecca L Purcell, Damian FJ Saksena, Nitin Wang, Bin Sonza, Secondo Wesselingh, Steven L Karlsson, Ingrid Fenyo, Eva-Maria Gabuzda, Dana Cunningham, Anthony L Gorry, Paul R |
author_sort | Sterjovski, Jasminka |
collection | PubMed |
description | BACKGROUND: CCR5-restricted (R5) human immunodeficiency virus type 1 (HIV-1) variants cause CD4+ T-cell loss in the majority of individuals who progress to AIDS, but mechanisms underlying the pathogenicity of R5 strains are poorly understood. To better understand envelope glycoprotein (Env) determinants contributing to pathogenicity of R5 viruses, we characterized 37 full-length R5 Envs from cross-sectional and longitudinal R5 viruses isolated from blood of patients with asymptomatic infection or AIDS, referred to as pre-AIDS (PA) and AIDS (A) R5 Envs, respectively. RESULTS: Compared to PA-R5 Envs, A-R5 Envs had enhanced fusogenicity in quantitative cell-cell fusion assays, and reduced sensitivity to inhibition by the fusion inhibitor T-20. Sequence analysis identified the presence of Asn 362 (N362), a potential N-linked glycosylation site immediately N-terminal to CD4-binding site (CD4bs) residues in the C3 region of gp120, more frequently in A-R5 Envs than PA-R5 Envs. N362 was associated with enhanced fusogenicity, faster entry kinetics, and increased sensitivity of Env-pseudotyped reporter viruses to neutralization by the CD4bs-directed Env mAb IgG1b12. Mutagenesis studies showed N362 contributes to enhanced fusogenicity of most A-R5 Envs. Molecular models indicate N362 is located adjacent to the CD4 binding loop of gp120, and suggest N362 may enhance fusogenicity by promoting greater exposure of the CD4bs and/or stabilizing the CD4-bound Env structure. CONCLUSION: Enhanced fusogenicity is a phenotype of the A-R5 Envs studied, which was associated with the presence of N362, enhanced HIV-1 entry kinetics and increased CD4bs exposure in gp120. N362 contributes to fusogenicity of R5 Envs in a strain dependent manner. Our studies suggest enhanced fusogenicity of A-R5 Envs may contribute to CD4+ T-cell loss in subjects who progress to AIDS whilst harbouring R5 HIV-1 variants. N362 may contribute to this effect in some individuals. |
format | Text |
id | pubmed-2225424 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-22254242008-02-03 Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS Sterjovski, Jasminka Churchill, Melissa J Ellett, Anne Gray, Lachlan R Roche, Michael J Dunfee, Rebecca L Purcell, Damian FJ Saksena, Nitin Wang, Bin Sonza, Secondo Wesselingh, Steven L Karlsson, Ingrid Fenyo, Eva-Maria Gabuzda, Dana Cunningham, Anthony L Gorry, Paul R Retrovirology Research BACKGROUND: CCR5-restricted (R5) human immunodeficiency virus type 1 (HIV-1) variants cause CD4+ T-cell loss in the majority of individuals who progress to AIDS, but mechanisms underlying the pathogenicity of R5 strains are poorly understood. To better understand envelope glycoprotein (Env) determinants contributing to pathogenicity of R5 viruses, we characterized 37 full-length R5 Envs from cross-sectional and longitudinal R5 viruses isolated from blood of patients with asymptomatic infection or AIDS, referred to as pre-AIDS (PA) and AIDS (A) R5 Envs, respectively. RESULTS: Compared to PA-R5 Envs, A-R5 Envs had enhanced fusogenicity in quantitative cell-cell fusion assays, and reduced sensitivity to inhibition by the fusion inhibitor T-20. Sequence analysis identified the presence of Asn 362 (N362), a potential N-linked glycosylation site immediately N-terminal to CD4-binding site (CD4bs) residues in the C3 region of gp120, more frequently in A-R5 Envs than PA-R5 Envs. N362 was associated with enhanced fusogenicity, faster entry kinetics, and increased sensitivity of Env-pseudotyped reporter viruses to neutralization by the CD4bs-directed Env mAb IgG1b12. Mutagenesis studies showed N362 contributes to enhanced fusogenicity of most A-R5 Envs. Molecular models indicate N362 is located adjacent to the CD4 binding loop of gp120, and suggest N362 may enhance fusogenicity by promoting greater exposure of the CD4bs and/or stabilizing the CD4-bound Env structure. CONCLUSION: Enhanced fusogenicity is a phenotype of the A-R5 Envs studied, which was associated with the presence of N362, enhanced HIV-1 entry kinetics and increased CD4bs exposure in gp120. N362 contributes to fusogenicity of R5 Envs in a strain dependent manner. Our studies suggest enhanced fusogenicity of A-R5 Envs may contribute to CD4+ T-cell loss in subjects who progress to AIDS whilst harbouring R5 HIV-1 variants. N362 may contribute to this effect in some individuals. BioMed Central 2007-12-12 /pmc/articles/PMC2225424/ /pubmed/18076768 http://dx.doi.org/10.1186/1742-4690-4-89 Text en Copyright © 2007 Sterjovski et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Sterjovski, Jasminka Churchill, Melissa J Ellett, Anne Gray, Lachlan R Roche, Michael J Dunfee, Rebecca L Purcell, Damian FJ Saksena, Nitin Wang, Bin Sonza, Secondo Wesselingh, Steven L Karlsson, Ingrid Fenyo, Eva-Maria Gabuzda, Dana Cunningham, Anthony L Gorry, Paul R Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS |
title | Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS |
title_full | Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS |
title_fullStr | Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS |
title_full_unstemmed | Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS |
title_short | Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS |
title_sort | asn 362 in gp120 contributes to enhanced fusogenicity by ccr5-restricted hiv-1 envelope glycoprotein variants from patients with aids |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2225424/ https://www.ncbi.nlm.nih.gov/pubmed/18076768 http://dx.doi.org/10.1186/1742-4690-4-89 |
work_keys_str_mv | AT sterjovskijasminka asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids AT churchillmelissaj asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids AT ellettanne asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids AT graylachlanr asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids AT rochemichaelj asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids AT dunfeerebeccal asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids AT purcelldamianfj asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids AT saksenanitin asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids AT wangbin asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids AT sonzasecondo asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids AT wesselinghstevenl asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids AT karlssoningrid asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids AT fenyoevamaria asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids AT gabuzdadana asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids AT cunninghamanthonyl asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids AT gorrypaulr asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids |